The Centre for Outcomes Research and Economic Evaluation for Health (C2H) is an esteemed department of the National Institute of Public Health in Japan, established in 2018. The organisation conducts rigorous academic research on cost-effectiveness evaluations and plays a crucial role in the official evaluation process. In a nation where public healthcare expenditure is continually increasing, C2H’s work is invaluable. They strive to balance the cost and outcome of healthcare technologies, providing crucial data and materials for evidence-based health policy. The ultimate goal is to enhance the sustainability of the public healthcare system. C2H is a beacon of knowledge for experts conducting cost-effectiveness evaluations, offering guidelines and analytical tools. Furthermore, they also guide manufacturers in conducting scientifically sound analyses and help citizens and healthcare professionals understand the value and implications of their evaluations. Below are some insights to Valbenazine market access.
In May 2023, Valbenazine was reimbursed and its drug price was set at JPY 2331.2 for a Dysval® capsule 40mg in Japan, determined via the Similar Efficacy Comparison Method with a 5% premium. This pricing strategy is an example of dynamic pricing, a common practice in pharmaceutical pricing strategy. The drug was designated for the Cost-effectiveness Evaluation with an H2 classification, reflecting its significant value story.
The target population for Valbenazine is patients with tardive dyskinesia whose symptoms have not improved sufficiently by reducing or discontinuing drugs for underlying diseases. Given the limited treatment options for this group, the comparator for the cost-effectiveness evaluation was “watchful waiting”.
The manufacturer conducted a systematic review of randomised controlled trials to evaluate the drug’s additional benefits. This review included a mixed-model meta-analysis that compared Valbenazine with a placebo. The results showed that Valbenazine significantly improved patients’ symptoms. This reaffirms the value-based healthcare benefits of the drug.
The manufacturer conducted a cost-utility analysis using a microsimulation model. This model accounted for responses from interventions, prescription of antipsychotic drugs, and recurrence of underlying diseases. Interestingly, the results of this analysis further substantiated the benefits of Valbenazine, demonstrating its cost-effectiveness and aligning with the principles of value-based healthcare 2024.
💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.
But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?
Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.
#SyenzaNews #healthcare #pricing
🌐 Are you ready to witness a paradigm shift in digital health technology?
The National Institute for Health and Care Excellence (NICE) has announced transformative reforms aimed at accelerating the adoption of digital health innovations within the NHS. By focusing on cost-effectiveness rather than mere cost savings, these changes promise to streamline regulatory processes and enhance evaluations aligned with healthcare priorities.
Dive into this insightful article to explore how NICE’s reforms could reshape the future of healthcare systems globally!
#SyenzaNews #DigitalHealth #HealthEconomics #Innovation
🚀 What could a groundbreaking partnership between BioNTech and Bristol-Myers Squibb mean for the future of solid tumor therapy?
Their collaboration on BNT327 is set to revolutionize immuno-oncology with promising early-phase trial results and a strategic investment of over $1.5 billion. This innovative bispecific antibody targets both PD-L1 and VEGF-A, indicating potential for enhanced patient outcomes in challenging cancers like small cell lung cancer and triple-negative breast cancer.
Curious about how this partnership could reshape cancer treatments? Dive into the full analysis!
#SyenzaNews #oncology #drugdevelopment #MarketAccess
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
